Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1001/jama.282.11.1038 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Methicillin-Resistant : The Shifting Landscape in the United Arab Emirates.
Antibiotics (Basel)
January 2025
College of Medicine, Mohammed Bin Rashid University of Medicine and Health Sciences, Dubai P.O. Box 505055, United Arab Emirates.
Background: Methicillin-resistant (MRSA) is a significant burden globally, particularly in the Arabian Gulf region. The United Arab Emirates (UAE) has experienced rising MRSA prevalence, with increasing diversity in the clonal complexes (CCs) identified. The COVID-19 pandemic, with its increased hospitalization rates and antibiotic use, may have further influenced MRSA's genetic evolution and epidemiology in the country.
View Article and Find Full Text PDFCeftobiprole: A therapeutic update.
Am J Health Syst Pharm
January 2025
Pharmacotherapy Department, Washington State University College of Pharmacy and Pharmaceutical Sciences, Spokane, WA, USA.
Disclaimer: In an effort to expedite the publication of articles, AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting and author proofing. These manuscripts are not the final version of record and will be replaced with the final article (formatted per AJHP style and proofed by the authors) at a later time.
View Article and Find Full Text PDFNew Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on ).
Antimicrob Agents Chemother
January 2025
Norton Infectious Diseases Institute, Norton Healthcare, Louisville, Kentucky, USA.
Omadacycline is a novel antimicrobial belonging to the tetracycline class. It has the ability to evade both efflux and ribosomal methylation types of resistance and therefore has an expanded spectrum compared to other tetracycline agents. Omadacycline is active against a number of multidrug-resistant bacteria, including macrolide and doxycycline-resistant methicillin-resistant (MRSA), vancomycin-resistant Enterococcus, and several enteric gram-negative bacilli.
View Article and Find Full Text PDFCeftobiprole activity against multidrug-resistant clinical isolates collected in the United States from 2016 through 2022.
Antimicrob Agents Chemother
January 2025
JMI Laboratories, Element Materials Technology, North Liberty, Iowa, USA.
Ceftobiprole was recently approved by the United States (US) Food and Drug Administration (FDA) for the treatment of adult patients with bacteremia, including right-side endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia in adults and pediatrics. Ceftobiprole is an advanced-generation cephalosporin approved in many countries for the treatment of adults with community-acquired pneumonia and hospital-acquired pneumonia, excluding ventilator-associated pneumonia. We evaluated the activities of ceftobiprole and comparators against methicillin-resistant (MRSA) and multidrug-resistant (MDR) clinical isolates.
View Article and Find Full Text PDFEarly-Stage IM Treatment with the Host-Derived Immunostimulant CPDI-02 Increases Curative Protection of Healthy Outbred Mice Against Subcutaneous Infection with Community-Acquired Methicillin-Resistant USA300.
Pharmaceutics
December 2024
Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198, USA.
: Community-acquired methicillin-resistant (CA-MRSA) greatly complicates the treatment of skin and soft tissue infections (SSTI). It was previously found that subcutaneous (SQ) treatment with the mononuclear phagocyte (MP)-selective activator complements peptide-derived immunostimulant-02 (CPDI-02; formerly EP67) and increases prophylaxis of outbred CD-1 mice against SQ infection with CA-MRSA. Here, we determined if treatment with CPDI-02 also increases curative protection.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!